The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
出版年份 2018 全文链接
标题
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
作者
关键词
-
出版物
Mucosal Immunology
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-06-16
DOI
10.1038/s41385-018-0050-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders
- (2018) Robert P. Hirten et al. Clinical Gastroenterology and Hepatology
- A Spectrum of Genetic Variants Contributes to Immune Defects and Pathogenesis of Inflammatory Bowel Diseases
- (2018) Holm H. Uhlig et al. GASTROENTEROLOGY
- Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
- (2018) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn’s Disease
- (2018) Leila Amininejad et al. GASTROENTEROLOGY
- Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn’s Disease
- (2018) Brian G. Feagan et al. GASTROENTEROLOGY
- DOP054 Vedolizumab in combination with steroids for induction therapy in Crohn’s disease: an exploratory analysis of the GEMINI 2 and GEMINI 3 studies
- (2018) B E Sands et al. Journal of Crohns & Colitis
- OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
- (2018) S Danese et al. Journal of Crohns & Colitis
- DOP049 Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
- (2018) D Tarabar et al. Journal of Crohns & Colitis
- Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation
- (2018) Scott M. Whitlock et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review
- (2018) Sareh Shahmohammadi et al. Multiple Sclerosis and Related Disorders
- Infliximab Concentration Thresholds During Maintenance Therapy Vary Based on the Therapeutic Outcome of Interest in Inflammatory Bowel Disease
- (2017) Shana Rakowsky et al. GASTROENTEROLOGY
- ANTI-PD-1 Induced Colitis: A Case Series of 25 Patients
- (2017) James Kim et al. GASTROENTEROLOGY
- Efficacy and Safety of Abrilumab in Subjects with Moderate to Severe Ulcerative Colitis: Results of a Phase 2B, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
- (2017) Niels Vande Casteele et al. GASTROENTEROLOGY
- Higher Levels of Infliximab may Alleviate the Need of Azathioprine Comedication in the Treatment of Patients with Crohn's Disease: A Sonic Post HOC Analysis
- (2017) Jean Frederic Colombel et al. GASTROENTEROLOGY
- Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
- (2017) Jean-Frederic Colombel et al. GASTROENTEROLOGY
- Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases
- (2017) Clara Abraham et al. GASTROENTEROLOGY
- Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease
- (2017) Jeffrey S. Hyams et al. GASTROENTEROLOGY
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest
- (2017) William J. Sandborn et al. GASTROENTEROLOGY
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
- (2017) L.C.S. De Vries et al. Journal of Crohns & Colitis
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Crohn's disease
- (2017) Joana Torres et al. LANCET
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
- (2017) Jean-Frederic Colombel et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab-induced Crohn’s disease
- (2017) Poornima Varma et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Clinical Genomics in Inflammatory Bowel Disease
- (2017) Holm H. Uhlig et al. TRENDS IN GENETICS
- Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease
- (2016) Clara Yzet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
- (2016) Silvio Danese et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
- (2016) Shomron Ben-Horin et al. Clinical Gastroenterology and Hepatology
- Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
- (2016) Gaik W. Tew et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- Integrin-based therapeutics: biological basis, clinical use and new drugs
- (2016) Klaus Ley et al. NATURE REVIEWS DRUG DISCOVERY
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review: colitis associated with anti-CTLA-4 therapy
- (2015) A. Gupta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables
- (2015) C. A. Siegel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease
- (2015) Robert Hirten et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
- (2015) L Peyrin-Biroulet et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn’s Disease and Effects of Natalizumab Therapy
- (2015) Emanuelle Bellaguarda et al. Clinical Gastroenterology and Hepatology
- The Pharmacokinetics of Biologics: A Primer
- (2015) Diane R. Mould DIGESTIVE DISEASES
- Apremilast: A Review in Psoriasis and Psoriatic Arthritis
- (2015) Emma D. Deeks DRUGS
- Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
- (2015) Reena Khanna et al. Expert Opinion On Drug Safety
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease
- (2015) Joana Torres et al. GASTROENTEROLOGY
- Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
- (2015) Joseph R. Maxwell et al. IMMUNITY
- Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease
- (2015) Carlos Fernandes et al. Immunotherapy
- Introducing Vedolizumab to Clinical Practice: Who, When, and How?
- (2015) RV Bryant et al. Journal of Crohns & Colitis
- Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
- (2015) Krisztina B. Gecse et al. Journal of Crohns & Colitis
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Crohn's disease management after intestinal resection: a randomised trial
- (2015) Peter De Cruz et al. LANCET
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease
- (2015) Giovanni Monteleone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
- (2015) B. Lo et al. SCIENCE
- Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
- (2015) Sang Hyoung Park et al. Expert Review of Gastroenterology & Hepatology
- Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease
- (2014) Silvio Danese et al. CURRENT DRUG TARGETS
- Biologics for Extraintestinal Manifestations of IBD
- (2014) Stephan Vavricka et al. CURRENT DRUG TARGETS
- The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease
- (2014) Holm H. Uhlig et al. GASTROENTEROLOGY
- Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease
- (2014) Nynne Nyboe Andersen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
- (2014) Desirée Schubert et al. NATURE MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sphingosine-1-Phosphate and Its Receptors: Structure, Signaling, and Influence
- (2013) Hugh Rosen et al. Annual Review of Biochemistry
- Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials
- (2013) R.R. Gerner et al. DIGESTIVE DISEASES
- Lymphoma: The Bête Noire of the Long-term Use of Thiopurines in Adult and Elderly Patients With Inflammatory Bowel Disease
- (2013) Laurent Beaugerie GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- α4β7integrin: beyond T cell trafficking
- (2013) Sarah L Kempster et al. GUT
- The Cytotoxic Effects of Certolizumab Pegol and Golimumab Mediated by Transmembrane Tumor Necrosis Factor α
- (2013) Naoyasu Ueda et al. INFLAMMATORY BOWEL DISEASES
- ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
- (2013) Silvio Danese et al. Journal of Crohns & Colitis
- Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism
- (2013) A Eken et al. Mucosal Immunology
- Dynamic regulatory network controlling TH17 cell differentiation
- (2013) Nir Yosef et al. NATURE
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe Early-Onset Colitis Revealing Mevalonate Kinase Deficiency
- (2013) M. Levy et al. PEDIATRICS
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
- (2012) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
- (2012) Paul Rutgeerts et al. GASTROENTEROLOGY
- Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- (2012) Xavier Hébuterne et al. GUT
- Mucosal healing in inflammatory bowel diseases: a systematic review
- (2012) Markus F Neurath et al. GUT
- Secukinumab failure in Crohn's disease: the yeast connection?
- (2012) Jean Frédéric Colombel et al. GUT
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Response to biologic therapy in Crohnʼs disease is improved with early treatment: An analysis of health claims data
- (2012) David T. Rubin et al. INFLAMMATORY BOWEL DISEASES
- Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis
- (2012) Clémentine Perrier et al. INFLAMMATORY BOWEL DISEASES
- IL-17 and TNF- Sustain Neutrophil Recruitment during Inflammation through Synergistic Effects on Endothelial Activation
- (2012) G. K. Griffin et al. JOURNAL OF IMMUNOLOGY
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
- (2012) David Laharie et al. LANCET
- Induction and molecular signature of pathogenic TH17 cells
- (2012) Youjin Lee et al. NATURE IMMUNOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical, serological and genetic predictors of inflammatory bowel disease course
- (2012) Laurent Beaugerie WORLD JOURNAL OF GASTROENTEROLOGY
- Inhibitory Smad7: Emerging Roles in Health and Disease
- (2012) Marco A. Briones-Orta et al. Current Molecular Pharmacology
- Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial
- (2011) Maria W. Greenwald et al. ARTHRITIS AND RHEUMATISM
- A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes
- (2011) EG Stefanich et al. BRITISH JOURNAL OF PHARMACOLOGY
- Rituximab in Active Ulcerative Colitis
- (2011) Elisabeth Calderón–Gómez et al. GASTROENTEROLOGY
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
- (2011) Edouard Louis et al. GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
- (2011) K. Leiper et al. GUT
- Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease
- (2011) Jean-Frédéric Colombel et al. INFLAMMATORY BOWEL DISEASES
- Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials
- (2011) Kenneth B. Gordon et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Biosimilar, biobetter and next generation therapeutic antibodies
- (2011) Alain Beck mAbs
- Mevalonate Kinase Deficiency: A Survey of 50 Patients
- (2011) B. Bader-Meunier et al. PEDIATRICS
- Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
- (2011) A. Puel et al. SCIENCE
- Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study
- (2010) S. Schreiber et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells
- (2010) Philip P. Ahern et al. IMMUNITY
- Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
- (2010) Sofia Buonocore et al. NATURE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of TGF- signaling by Smad7
- (2009) X. Yan et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease
- (2009) M J L Romberg-Camps et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Interleukin-23/Th17 pathways and inflammatory bowel disease
- (2009) Clara Abraham et al. INFLAMMATORY BOWEL DISEASES
- Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohnʼs disease†
- (2009) Daniel J. Stein et al. INFLAMMATORY BOWEL DISEASES
- A protective function for interleukin 17A in T cell–mediated intestinal inflammation
- (2009) William O'Connor Jr et al. NATURE IMMUNOLOGY
- Hepatosplenic T cell lymphoma in inflammatory bowel disease
- (2008) M. Shale et al. GUT
- Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease
- (2008) D. E. Fassi et al. GUT
- Innate and Adaptive Interleukin-22 Protects Mice from Inflammatory Bowel Disease
- (2008) Lauren A. Zenewicz et al. IMMUNITY
- A review of the current use of rituximab in autoimmune diseases
- (2008) Hakan M. Gürcan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The comeback kid: TYSABRI now FDA approved for Crohn disease
- (2008) Karen Honey JOURNAL OF CLINICAL INVESTIGATION
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started